Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Third Rock Continues To Attract Investors, Closes $516M Fund

This article was originally published in The Pink Sheet Daily

Executive Summary

The biotech venture firm continues to draw investors despite lacking a large number of exits for its portfolio companies. Its third fund brought in the largest investment yet for the firm.

You may also be interested in...



Venture Investing In Biotech Still Strong, Says E&Y Report

The 27th annual Beyond Borders report shows continued constraints to funding for biotechs, as they cut R&D and deal with a changing development landscape, but VC funding remains resilient.

Cydan Hopes To Accelerate Rare Disease Drug Development With $16M Raise

The Massachusetts start-up has plans to create five new companies that will focus on rare disease work through an innovative business model that will de-risk the assets before spinning them out into separate biotech companies.

Shire Adds To HGT Unit With Lotus Acquisition; Gets Preclinical Rare Disease Treatment

Shire makes a bolt-on acquisition that will complement both its rare disease franchise and its regenerative medicines unit.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS075448

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel